Psych Editorial
  • Home
  • Contact

Meet the Executive Eli Lilly and Company Leadership Team: Maria Crowe

Meet the Executive Eli Lilly and Company Leadership Team: Maria Crowe 

Maria Crowe became president of global manufacturing operations on January 1, 2012, leading a global network of 23 sites in 13 countries. She also has responsibility for Lilly’s global contract-manufacturing organization.

In her previous role as senior vice president for global drug product manufacturing, a post she held since August 2009, Crowe oversaw drug-product manufacturing, packaging, and distribution operations in 11 countries. This included sites that manufacture tablets and capsules as well as those that manufacture injectable products formulated into vials, injection pens, and other delivery methods. Crowe also was responsible for emerging markets manufacturing, external drug-product operations, and U.S. distribution.

From 2007-2009, Crowe was vice president for drug product manufacturing in the Americas (the United States and Latin America). She previously was general manager at Lilly’s Kinsale, Ireland, plant for two years, general manager of Lilly del Caribe in Puerto Rico for five years, and plant manager of Lilly’s Elanco manufacturing plant at the former Tippecanoe site for one year. In her 29-year Lilly career, Crowe has held numerous roles in dry products, parenteral products, and API manufacturing, as well as in sourcing and procurement.

Crowe’s business-management experience includes responsibilities for the start-up of two new Lilly sites in Puerto Rico, as well as planning for the new biotech operation at Kinsale.

Crowe holds a bachelor’s degree in industrial management (with a minor in computer science) from Purdue University in West Lafayette, Indiana. She is a member of Purdue’s Krannert School of Management Dean’s Advisory Council, and she sits on the advisory board of Purdue’s Global Policy Research Institute.

Source: Eli Lilly and Co. Press Releases – Executive Bios

Related Posts

Takeda Pharmaceuticals

Takeda and Lundbeck Announce FDA Approval of Brintellix™ (vortioxetine) for Treatment of Adults with Major Depressive Disorder

Eli Lilly and Co., Executive Bios

Meet the Executive Eli Lilly and Company Leadership Team: Fionnuala M. Walsh

Eli Lilly and Co., Executive Bios

Meet the Executive Eli Lilly and Company Leadership Team: Jacques Tapiero

News & Views

  • Now Accepting Content
  • Takeda and Lundbeck Announce FDA Approval of Brintellix™ (vortioxetine) for Treatment of Adults with Major Depressive Disorder
  • Introducing the New Kid on the Block to Treat Depression: “Brintellix”.
  • Meet the Executive Eli Lilly and Company Leadership Team: Fionnuala M. Walsh
  • Meet the Executive Eli Lilly and Company Leadership Team: Jacques Tapiero
Psych Editorial
Copyright © PhysicianEditorial.com
All Rights Reserved!